InvestorRoom D http://immunepharmaceuticals.investorroom.com/ Immune Pharmaceuticals announces initiation of enrollment in clinical trial with CepleneĀ®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) http://immunepharmaceuticals.investorroom.com/2017-06-20-Immune-Pharmaceuticals-announces-initiation-of-enrollment-in-clinical-trial-with-Ceplene-R-low-dose-IL-2-in-Chronic-Myelomonocytic-Leukemia-CMML Immune's subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene Tue, 20 Jun 2017 09:14:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-20-Immune-Pharmaceuticals-announces-initiation-of-enrollment-in-clinical-trial-with-Ceplene-R-low-dose-IL-2-in-Chronic-Myelomonocytic-Leukemia-CMML Immune Receives NASDAQ Compliance Letter http://immunepharmaceuticals.investorroom.com/2017-06-19-Immune-Receives-NASDAQ-Compliance-Letter Mon, 19 Jun 2017 08:30:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-19-Immune-Receives-NASDAQ-Compliance-Letter Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene http://immunepharmaceuticals.investorroom.com/2017-06-15-Immune-Pharmaceuticals-Signs-Agreement-to-Regain-Worldwide-Rights-for-Ceplene Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America Thu, 15 Jun 2017 09:28:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-15-Immune-Pharmaceuticals-Signs-Agreement-to-Regain-Worldwide-Rights-for-Ceplene Immune Receives Nasdaq Letters http://immunepharmaceuticals.investorroom.com/2017-05-26-Immune-Receives-Nasdaq-Letters Fri, 26 May 2017 08:30:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-05-26-Immune-Receives-Nasdaq-Letters Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million http://immunepharmaceuticals.investorroom.com/2017-05-04-Immune-Pharmaceuticals-Announces-Private-Placement-of-up-to-3-4-Million Thu, 04 May 2017 09:00:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-05-04-Immune-Pharmaceuticals-Announces-Private-Placement-of-up-to-3-4-Million